REUTERS: Novartis has reached an agreement with U.S. regulators to hold a randomized trial of generic malaria drug hydroxychloroquine against COVID-19 disease in 440 hospitalized patients, the Swiss drug-maker said on Monday. The decades-old medicine has received U.S. Food and Drug Administration (FDA) emergency use authorization for Coronavirus disease, but so far there is no scientific proof it helps those